Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

485

Participants

Timeline

Start Date

October 11, 2018

Primary Completion Date

August 25, 2020

Study Completion Date

August 25, 2020

Conditions
Prostate Cancer
Interventions
DRUG

Ga-68 labeled PSMA-11

Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if there is presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.

DEVICE

Positron emission tomography-computed tomography (PET/CT)

Positron emission tomography-computed tomography (PET/CT) is a nuclear medicine technique which combines, in a single gantry, a positron emission tomography (PET) scanner and an x-ray computed tomography (CT) scanner, to acquire sequential images from both devices in the same session

DEVICE

Positron emission tomography-magnetic resonance imaging (PET/MRI)

A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan in a single session

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

All Listed Sponsors
lead

Thomas Hope

OTHER

NCT03803475 - Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients | Biotech Hunter | Biotech Hunter